TargED Biopharmaceuticals (“TargED”), is a private biotechnology company focused on developing improved treatments for thrombotic diseases. Their lead product, Microlyse, is a first-in-class proprietary clot-busting compound which binds to a protein present in all forms of thrombosis. Microlyse is the first compound to achieve targeted enzyme delivery, using a single domain antibody (VhH), directly to blood clots.
Year of investment
2022
Sector
Biotechnology
Location
Utrecht, Netherlands